trending Market Intelligence /marketintelligence/en/news-insights/trending/78IbMMJn8rY5pqjBd9Ek6g2 content esgSubNav
In This List

UK's NICE recommends Celgene pancreatic cancer drug for use in NHS

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


UK's NICE recommends Celgene pancreatic cancer drug for use in NHS

The U.K.'s National Institute for Health and Care Excellence, or NICE, recommended Celgene Corp.'s pancreatic cancer drug Abraxane for routine use in the National Health Service.

Celgene agreed to a confidential price discount to make the drug more cost-effective.

Abraxane can extend the life of pancreatic cancer patients by an average of 2.4 months when added to standard chemotherapy.

The life expectancy of pancreatic cancer patients is up to six months. There are almost 10,000 new cases of pancreatic cancer each year in the U.K.